Malignant mesothelioma stands as a formidable adversary in oncology, a rare and exceptionally aggressive cancer primarily associated with occupational or environmental exposure to asbestos fibers. When these microscopic, needle-like particles are inhaled, they can become irrevocably lodged within the delicate lining of the lungs, initiating a cascade of cellular damage and chronic inflammation that, tragically, often culminates in tumor development many decades after initial exposure. With an estimated 30,000 new diagnoses reported globally each year, the stark reality for individuals afflicted with this devastating disease is a prognosis defined by limited therapeutic options and a distressingly short median survival, typically around a mere 12 months. The five-year survival rate, a critical benchmark for cancer outcomes, languishes at approximately 10 percent, underscoring the urgent and profound unmet medical need in this patient population. Historically, many of those affected are men who previously worked in heavy industries such as shipbuilding, oil refining, and asbestos manufacturing, occupations that carried a high risk of exposure before stricter regulations were implemented. Existing treatments, which include combinations of surgery, radiation, chemotherapy, and, more recently, immunotherapy, offer some respite and can prolong life for certain patients, yet the disease frequently proves stubbornly resistant to control. The profound challenge presented by mesothelioma has driven researchers worldwide to seek innovative strategies, pushing the boundaries of scientific understanding to devise more effective interventions.
A groundbreaking study, recently published in the esteemed journal Nature Communications, details a novel therapeutic approach that holds significant promise for transforming the treatment landscape of mesothelioma and potentially other malignancies. This pivotal research, spearheaded by an international collaborative team including Professor Brian Cunniff and research scientist Victoria Gibson from the University of Vermont (UVM), describes an unconventional strategy that turns a fundamental aspect of cancer cell biology against itself. Rather than bolstering the body’s defenses, this method exploits an inherent vulnerability within tumor cells, leveraging their protective systems as a pathway to destruction.
Central to this innovative strategy is the concept of oxidative stress, a biological phenomenon that plays a critical role in the life and death of cells. Cancer cells, characterized by their hyperactive metabolisms and rapid proliferation, inherently generate unusually high quantities of "reactive oxygen species" (ROS). These unstable molecules, which include hydrogen peroxide, are byproducts of metabolic processes and, if left unchecked, can inflict substantial damage on cellular components like DNA, proteins, and lipids, ultimately leading to cell dysfunction or death. To counteract this constant internal assault and ensure their survival, tumor cells, much like normal cells but to a far greater degree, ramp up the production of a sophisticated array of antioxidant enzymes. Among these crucial defenses is peroxiredoxin 3, or PRX3, an enzyme specifically localized within the mitochondria – the cell’s vital powerhouses responsible for generating most of its energy.
For decades, the prevailing scientific hypothesis in cancer research suggested that increasing antioxidant levels might help combat the disease by neutralizing damaging ROS. However, numerous clinical trials based on this premise largely failed to yield positive results, and some studies even indicated that an overabundance of antioxidants could inadvertently aid tumor growth by protecting cancer cells from their own internally generated oxidative stress. The UVM research team, with a stroke of elegant scientific reasoning, opted to reverse this conventional logic. Instead of asking how to increase antioxidants, they posed a different, more provocative question: What would happen if cancer cells were deliberately deprived of one of their most critical antioxidant defenses? Their innovative approach focuses on precisely blocking PRX3. Without the protective action of this essential enzyme, oxidative stress within the tumor cells accumulates unchecked, building to catastrophic levels that ultimately overwhelm the cell’s capacity for repair and trigger programmed cell death, or apoptosis.
The experimental therapeutic agent developed by RS Oncology, LLC, known as RSO-021, emerged directly from these foundational discoveries made at the University of Vermont. This compound is a clinical formulation derived from thiostrepton, a naturally occurring antibiotic that was found to be highly effective in disabling PRX3. By inhibiting PRX3, RSO-021 causes hydrogen peroxide to build up specifically within the mitochondria of tumor cells. This targeted accumulation of a highly reactive molecule creates an internal toxic environment, leading to a cascade of cellular damage that culminates in the demise of the cancer cell. The inherent metabolic peculiarities of cancer cells render them particularly susceptible to this strategy. Because tumor cells already produce significantly more ROS than healthy cells, they are precariously balanced on the edge of oxidative overload. Furthermore, PRX3 exhibits a more rapid turnover rate in malignant cells compared to healthy tissues, suggesting that RSO-021 could selectively target cancer cells while sparing healthy, non-malignant tissue, thereby minimizing potential side effects.
Rigorous laboratory experiments provided compelling preclinical evidence supporting the critical role of PRX3 in mesothelioma survival. When researchers genetically engineered mesothelioma tumor cell lines to completely eliminate PRX3, the results were striking: mitochondrial function declined precipitously, cellular growth slowed dramatically, and, crucially, these cancer cells were no longer able to form tumors in animal models. These findings underscored PRX3’s indispensable role in maintaining the viability and tumorigenicity of mesothelioma cells. Moreover, other independent research groups have demonstrated that genetically eliminating PRX3 in healthy mice does not result in any adverse health effects. This critical observation directly addresses a long-standing concern among some scientists who questioned the safety of targeting mitochondria, given their fundamental role in nearly every cell’s essential functions. As Victoria Gibson, the lead author of the study, succinctly put it, "People will come up to us at conferences and state that you can’t target the mitochondria because they’re too important. The evidence – that you can knock out PRX3 in mice and there’s no adverse phenotype – supports our approach." This means that even without the genes responsible for producing PRX3, mice can develop and function entirely normally, providing a strong safety signal for this targeted therapeutic strategy.
The journey of RSO-021 from a UVM laboratory bench to human patients began around 2015 at the university’s Cancer Center. Following initial experiments with thiostrepton that yielded highly encouraging results, the UVM researchers played a pivotal role in establishing RS Oncology, a private pharmaceutical company specifically created to advance these promising discoveries toward clinical testing. Professor Brian Cunniff, an associate professor in the Department of Pathology and Laboratory Medicine at UVM’s Larner College of Medicine, also serves as the company’s chief science officer, bridging academic innovation with pharmaceutical development. The team meticulously refined thiostrepton into RSO-021, a robust clinical formulation ready for human trials.
Between 2022 and 2023, RSO-021 entered a critical phase one clinical trial conducted in the United Kingdom, under the stringent regulatory oversight of the Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s equivalent of the U.S. Food and Drug Administration (FDA). A key aspect of the treatment’s administration capitalizes on a common complication of mesothelioma: pleural effusions. Approximately 90 percent of mesothelioma patients develop these fluid buildups in the pleural space, the area between the lung and the chest wall. Consequently, many patients already have a catheter in place to manage these effusions. This anatomical accessibility allowed RSO-021 to be delivered directly into the chest cavity. This localized delivery method is strategically advantageous, as it allows for a high concentration of the drug to reach the tumor site, maximizing its therapeutic effect while simultaneously minimizing the amount of medication circulating systemically throughout the rest of the body, thereby reducing potential off-target side effects.
The results from the phase one study were highly encouraging and met all primary safety and tolerability endpoints at a dose of 90 milligrams. Crucially, no patient deaths were attributed to the experimental drug. Beyond safety, researchers also collected patient tissue samples, which provided irrefutable evidence that RSO-021 was indeed engaging its intended biological target within human tumors, precisely as observed in preclinical cell and animal models. This confirmation of mechanism of action in human subjects is a vital milestone in drug development. From a therapeutic efficacy standpoint, the trial demonstrated significant clinical benefit: disease progression was controlled in an impressive 67% of participants, and some patients even experienced a measurable shrinkage of their tumors. While the average progression-free survival (PFS) was 4.2 months, a duration roughly comparable to existing standard treatments, the researchers were particularly heartened by the overall survival (OS) data. Among the 15 patients in the cohort, many of whom were critically ill and had exhausted other treatment options, survival rates were markedly better than those typically observed with currently available therapies for such advanced disease. Professor Cunniff characterized this finding as a potential "game changer," expressing cautious optimism that "Our overall survival data is very promising and will hopefully persist with additional patients." Intriguingly, initial findings also suggest that RSO-021’s benefits may extend beyond direct cytotoxic activity. The drug appears to possess an immunomodulatory capacity, potentially altering the tumor’s microenvironment in a way that primes or enhances the body’s own immune system to recognize and attack or restrain the cancer. As Cunniff elaborated, "Our drug has both cytotoxic activity, it can kill the tumor cells, but it also has immunomodulatory capacity where it can modulate the immune system to now manage the tumor." Building on these promising phase one results, phase two of the clinical trial has now concluded, and the scientific community eagerly awaits the presentation of its findings at an upcoming global oncology meeting this year.
The research trajectory for this innovative therapeutic strategy is now diversifying into several promising avenues. Collaborators from UVM and RS Oncology, working in conjunction with institutions like the University of Leicester and other partners in the UK, are actively engaged in developing second-generation PRX3 inhibitors. These next-generation compounds aim to improve solubility and other pharmacokinetic properties, with the ultimate goal of formulating them into more convenient delivery methods. The potential for future versions to be administered as an oral tablet would represent a significant advancement, making the treatment far easier to manage for patients and potentially broadening its applicability beyond mesothelioma to a wider spectrum of cancers. At the University of Vermont, Victoria Gibson, the lead author of the pivotal Nature Communications study, continues her dedicated work as a postdoctoral researcher. She is spearheading investigations into the potential utility of thiostrepton in various peritoneal malignancies, a group of cancers affecting the lining of the abdominal cavity. This includes peritoneal mesothelioma, as well as gastric cancer and other gastrointestinal cancers. This collaborative effort involves Conor O’Neill, a surgical oncologist at the UVM Cancer Center and UVM Health, further strengthening the translational bridge between fundamental research and clinical application. "We believe this mechanism could be applicable to other cancers," Professor Cunniff affirmed, highlighting the broad therapeutic potential of this targeted mitochondrial approach.
For Victoria Gibson, witnessing the progression of this research from initial laboratory experiments to the tangible impact on human patients has instilled a profound and deeply personal dimension to her scientific endeavors. "I’ve always just had a desire to help people because I feel like everyone has experienced cancer in their life, whether it’s them, friends, or family members," she shared. Despite her unwavering commitment to the cause, she recounted a particularly poignant moment of realization when a family member reached out to the laboratory, hoping to enroll her dying father in the very clinical trial that sprang from Gibson’s work. "We just work in a lab all day working with cells," she recalled, reflecting on the often-abstract nature of basic research, "and the fact that we’re making an impact on people, that they’re wanting to be on this clinical trial, just was amazing to me." This powerful testament underscores the immense human impact of translational science, transforming complex biological insights into tangible hope for patients facing some of the most challenging diseases.
About the Author
